Anti-inflammatory effects of macrolides in lung disease

Pediatric Pulmonology

Volumn 31, Issue 6, 2001, Pages 464-473

  Jaff, Adam ^a   Bush, Andrew ^b  

^a GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^b ROYAL BROMPTON AND HAREFIELD NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Asthma; Bronchiectasis; Cystic fibrosis; Inflammation; Macrolides; Panbronchiolitis

Indexed keywords

MACROLIDE; MULTIDRUG RESISTANCE PROTEIN;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHOSPASM; CYSTIC FIBROSIS; DOSE RESPONSE; DRUG INDUCED DISEASE; HUMAN; NEUTROPHIL; PRIORITY JOURNAL; REVIEW; SURVIVAL;

ANTI-BACTERIAL AGENTS; ASTHMA; BIOFILMS; BRONCHIECTASIS; BRONCHIOLITIS; BRONCHOCONSTRICTION; CYSTIC FIBROSIS; HUMANS; INFLAMMATION; LUNG DISEASES; MACROLIDES; NEUTROPHILS; RANDOMIZED CONTROLLED TRIALS;

EID: 0035006420     PISSN: 87556863     EISSN: None     Source Type: Journal    
DOI: 10.1002/ppul.1076     Document Type: Review

References (104)

1. The use of triacetyloleandomycin in chronic infectious asthma
2. Diffuse panbronchiolitis in an Asian immigrant
3. Long-term low-dose administration of erythromycin to patients with diffuse panbronchiolitis
4. Interleukin 1 beta, tumor necrosis factor alpha, and interleukin 8 in bronchoalveolar lavage fluid of patients with diffuse panbronchiolitis: A potential mechanism of macrolide therapy
5. Diffuse panbronchiolitis: Efficacy of low-dose erythromycin
6. Diffuse panbronchiolitis and cystic fibrosis: East meets West
7. History of macrolide use in pediatrics
8. Future indications for macrolides
9. Mediastinal lymphadenopathy caused by Mycobacterium aviumintracellulare complex in a child with normal immunity
10. Bronchial responsiveness and acute bronchodilator response in chronic obstructive pulmonary disease and diffuse panbronchiolitis
11. Neutrophilia in bronchoalveolar lavage fluid of diffuse panbronchiolitis
12. Identification of novel mutations of the CFTR gene in a Japanese patient with cystic fibrosis
13. Delta F508 mutation of cystic fibrosis gene is not found in chronic bronchitis with severe obstruction in Japan
14. Diffuse panbronchiolitis is closely associated with mutations of the CFTR gene
15. A mechanism of erythromycin treatment in patients with diffuse panbronchiolitis
16. Erythromycin inhibits neutrophil chemotaxis in bronchoalveoli of diffuse panbronchiolitis
17. Erythromycin reduces neutrophils and neutrophil-derived elastolytic-like activity in the lower respiratory tract of bronchiolitis patients
18. Effect of erythromycin on Haemophilus influenzae endotoxin-induced release of IL-6, IL-8 and sICAM-1 by cultured human bronchial epithelial cells
19. Roxithromycin inhibits cytokine production by and neutrophil attachment to human bronchial epithelial cells in vitro
20. Elevated concentrations of defensins in bronchoalveolar lavage fluid in diffuse panbronchiolitis
21. Elevated levels of soluble adhesion molecules in serum of patients with diffuse panbronchiolitis
22. Erythromycin modulates IL-8 expression in normal and inflamed human bronchial epithelial cells
23. Macrolide antibiotics in diffuse panbronchiolitis and in cystic fibrosis
24. Human peripheral blood eosinophils produce and release interleukin-8 on stimulation with calcium ionophore
25. Interleukin-8 is a potent mediator of eosinophil chemotaxis through endothelium and epithelium
26. Fourteen-member macrolides inhibit interleukin-8 release by human eosinophils from atopic donors
27. Interleukin-8 gene repression by clarithromycin is mediated by the activator protein-1 binding site in human bronchial epithelial cells
28. Erythromycin suppresses nuclear factor-kappaB and activator protein-1 activation in human bronchial epithelial cells
29. Erythromycin inhibition of lipopolysaccharide-stimulated tumor necrosis factor alpha production by human monocytes in vitro
30. Erythromycin inhibits tumor necrosis factor alpha and interleukin 6 production induced by heat-killed Streptococcus pneumoniae in whole blood
31. In vitro and ex vivo effects of recent and new macrolide antibiotics on chemotaxis of human polymorphonuclear leukocytes
32. Studies on the effects of ingestion of a single 500 mg oral dose of erythromycin stearate on leucocyte motility and transformation and on release in vitro of prostaglandin E2 by stimulated leucocytes
33. Erythromycin and roxithromycin potentiate human neutrophil locomotion in vitro by inhibition of leukoattractant-activated superoxide generation and autooxidation
34. Comparison of the in vitro effect of several macrolides on the oxidative burst of human neutrophils
35. Effects of erythromycin on chemoattractant-activated human polymorphonuclear leukocytes
36. Antibiotic inhibition of the respiratory burst response in human polymorphonuclear leukocytes
37. Erythromycin shortens neutrophil survival by accelerating apoptosis
38. A novel potent vasoconstrictor peptide produced by vascular endothelial cells
39. Contractile activity of three endothelins (ET-1, ET-2 and ET-3) on the human isolated bronchus
40. Erythromycin and clarithromycin attenuate cytokine-induced endothelin-1 expression in human bronchial epithelial cells
41. Effects of macrolide antibiotics on neurally mediated contraction of human isolated bronchus
42. Biofilm disease: Its clinical manifestation and therapeutic possibilities of macrolides
43. Antibiotic treatment of initial colonization with Pseudomonas aeruginosa postpones chronic infection and prevents deterioration of pulmonary function in cystic
44. Effect on Pseudomonas aeruginosa alginate expression of direct plating and culture of fresh cystic fibrosis sputum on to Pseudomonas isolation agar containing subinhibitory concentrations of roxithromycin and rifampicin
45. Pseudomonas aeruginosa infection in cystic fibrosis and its management
46. Azithromycin treatment inhibits induction of mucoid phenotype in susceptible BALB/c mice with chronic Pseudomonas aeruginosa lung infection
47. Quantitative effect of roxithromycin and rifampicin on mucoid cultures from directly plated sputum of cystic fibrosis patients chronically colonized with Pseudomonas aeruginosa
48. The influence of azithromycin on the biofilm formation of Pseudomonas aeruginosa in vitro
49. Erythromycin inhibits respiratory glycoconjugate secretion from human airways in vitro
50. Effect of macrolide antibiotics on airway goblet hypersecretion in guinea pigs. Kansenshogaku Zasshi
51. Effect of azithromycin treatment on sputum rheology in cystic fibrosis patients
52. The effects of azithromycin therapy on sputum inflammation in CF lung disease
53. Effect of clarithromycin on nasal mucus properties in healthy subjects and in patients with purulent rhinitis
54. Effect of clarithromycin on experimental rhinovirus-16 colds: A randomized, double-blind, controlled trial
55. CFTR gene transfer reduces the binding of Pseudomonas aeruginosa to cystic fibrosis respiratory epithelium
56. Antimicrobial activity of clarithromycin and its effect on bacterial adherence to medical material
57. Adherence of Pseudomonas aeruginosa to mouse tracheal epithelium - The effect of antimicrobial agents. Kansenshogaku Zasshi
58. Azithromycin reduces epithelial adherence of P. aeruginosa in patients with cystic fibrosis
59. Induction by antitumoral drugs of proteins that functionally complement CFTR: A novel therapy for cystic fibrosis?
60. Dramatic improvement of cystic fibrosis during and after antitumorous chemotherapy: A report of three cases
61. In vivo induction of liver P-glycoprotein expression by xenobiotics in monkeys
62. Azithromycin, the multidrug-resistant protein, and cystic fibrosis
63. The changing epidemiology of cystic fibrosis
64. Long-term azithromycin may improve lung function in children with cystic fibrosis
65. Azithromycin improves pulmonary symptoms in patients with CF
66. An observational report of the use of azithromycin in cystic fibrosis
67. Long-term macrolide antibiotics improve pulmonary function in cystic fibrosis
68. Effect of chronic azithromycin on lung function in cystic fibrosis
69. Effect of clarithromycin on airway obstruction and sputum neutrophilia in patients with cystic fibrosis
70. Macrolide antibiotics for cystic fibrosis
71. A pilot study of low-dose erythromycin in bronchiectasis
72. Effect of roxithromycin on airway responsiveness in children with bronchiectasis: A double-blind, placebo-controlled study
73. The use of macrolide antibiotic substances in the treatment of asthma
74. Efficacy of troleandomycin in outpatients with severe, corticosteroid-dependent asthma
75. An improved protocol for the use of troleandomycin (TAO) in the treatment of steroid-requiring asthma
76. Troleandomycin in the treatment of difficult asthma
77. A double-blind study of troleandomycin and methylprednisolone in asthmatic subjects who require daily corticosteroids
78. Methylprednisolone and troleandomycin in treatment of steroid-dependent asthmatic children
79. Effect of low-dose troleandomycin on glucocorticoid pharmacokinetics and airway hyperresponsiveness in severely asthmatic children
80. Efficacy and safety of low-dose troleandomycin therapy in children with severe, steroid-requiring asthma
81. Benefits and complications of troleandomycin (TAO) in young children with steroid-dependent asthma
82. Roxithromycin reduces the degree of bronchial hyperresponsiveness in children with asthma
83. Inhibition of methylprednisolone elimination in the presence of clarithromycin therapy
84. The effect of troleandomycin on methylprednisolone elimination
85. Inhibition of methylprednisolone elimination in the presence of erythromycin therapy
86. The incidence of corticosteroid side effects in chronic steroid-dependent asthmatics on TAO (troleandomycin) and methylprednisolone
87. The use of macrolides in the treatment of asthma
88. Use of TAO without methylprednisolone in the treatment of severe asthma
89. Erythromycin reduces the severity of bronchial hyperresponsiveness in asthma
90. Clarithromycin suppresses bronchial hyperresponsiveness associated with eosinophilic inflammation in patients with asthma
91. Effect of erythromycin on theophylline clearance in asthmatic children
92. Evidence that severe asthma can be divided pathologically into two inflammatory subtypes with distinct physiologic and clinical characteristics
93. Increased neutrophil numbers and IL-8 levels in airway secretions in acute severe asthma. Clinical and biological significance
94. The association of Chlamydia pneumoniae infection and reactive airway disease in children
95. Chlamydia pneumoniae and asthma
96. Evidence for Chlamydia pneumoniae infection in steroid-dependent asthma
97. Serological evidence of infection with Chlamydia pneumoniae is related to the severity of asthma
98. Chlamydia pneumoniae infection in children with persistent cough
99. Detection of Mycoplasma pneumoniae in the airways of adults with chronic asthma
100. Immunomodulation as asthma therapy: Where do we stand?
101. Interaction of macrolides with alpha dornase during DNA hydrolysis
102. Erythromycin inhibits C1 secretion across canine tracheal epithelial cells
103. Non-tuberculous mycobacteria in cystic fibrosis
104. The effect of changes in the consumption of macrolide antibiotics on erythromycin resistance in group A streptococci in Finland. Finnish Study Group for Antimicrobial Resistance